All Products are stable to be shipped at room temperature, unless otherwise specified.
| Pack Size | Quantity | Price (USD) | Sub Total |
|---|---|---|---|
| 2.5mg | $ 50.00 | 0.0 | |
| 5mg | $ 90.00 | 0.0 | |
| 10mg | $ 130.00 | 0.0 | |
| 25mg | $ 240.00 | 0.0 | |
| 100mg | $ 625.00 | 0.0 | |
| 250mg | $ 870.00 | 0.0 | |
| Exact Weight Packaging | $ 145.00 | 0.0 | |
| Total | $ 0.0 | ||
Product successfully added to cart.
- Request another packsize ? Click here.
- Inventory Status : In Stock
- Ships On :
A115605
Bulk Order Request for A115605
Product Description
| Catalogue Number | A115605 |
| Chemical Name | Acalabrutinib |
| Synonyms | 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide; ACP 196 |
| CAS Number | 1420477-60-6 |
| Molecular Formula | C₂₆H₂₃N₇O₂ |
| Appearance | Light Yellow to Yellow Solid |
| Melting Point | >133°C (dec.) |
| Molecular Weight | 465.51 |
| Storage | 4°C |
| Solubility | DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly) |
| Category | Standards; Pharmaceutical/API Drug Impurities/Metabolites; |
| Applications | Acalabrutinib, is an experimental anti-cancer drug and a selective Bruton's tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL). |
| References | 'Byrd; et al. (2015). ''Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.''; ''AstraZeneca to buy Acerta for blood cancer drug''. www.rsc.org. Chemistry World - Royal Society of Chemistry. Retrieved 24 December 2015.' |